Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ubenimex in Adult Patients With Lymphedema of The Lower Limb: a Phase 2, RAndomized, Double-blind, Placebo-controlled Study of Efficacy, Safety, and Pharmacokinetics (ULTRA)

Next Previous
Trial Profile

Ubenimex in Adult Patients With Lymphedema of The Lower Limb: a Phase 2, RAndomized, Double-blind, Placebo-controlled Study of Efficacy, Safety, and Pharmacokinetics (ULTRA)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ubenimex (Primary)
  • Indications Lymphoedema
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ULTRA
  • Sponsors Eiger BioPharmaceuticals

Most Recent Events

  • 15 Jul 2019 Status changed from active, no longer recruiting to completed.
  • 12 Nov 2018 Planned End Date changed from 1 Nov 2018 to 1 feb 2019.
  • 16 Oct 2018 Primary endpoint (Change in skin thickness of the calf of the most affected leg, measured by skinfold calipers) has not been met.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top